A penalized expectation of determinant (ED)-optimal design with a discrete parameter distribution was used to find an optimal experimental design for assessment of enzyme kinetics in a screening environment. A data set for enzyme kinetic data (V max and K m ) was collected from previously reported studies, and every V max /K m pair (n ‫؍‬ 76) was taken to represent a unique drug compound. The design was restricted to 15 samples, an incubation time of up to 40 min, and starting concentrations (C 0 ) for the incubation between 0.01 and 100 M. The optimization was performed by finding the sample times and C 0 returning the lowest uncertainty (S.E.) of the model parameter estimates. Individual optimal designs, one general optimal design and one, for laboratory practice suitable, pragmatic optimal design (OD) were obtained. In addition, a standard design (STD-D), representing a commonly applied approach for metabolic stability investigations, was constructed. Simulations were performed for OD and STD-D by using the Michaelis-Menten (MM) equation, and enzyme kinetic parameters were estimated with both MM and a monoexponential decay. OD generated a better result (relative standard error) for 99% of the compounds and an equal or better result [(root mean square error (RMSE)] for 78% of the compounds in estimation of metabolic intrinsic clearance. Furthermore, high-quality estimates (RMSE < 30%) of both V max and K m could be obtained for a considerable number (26%) of the investigated compounds by using the suggested OD. The results presented in this study demonstrate that the output could generally be improved compared with that obtained from the standard approaches used today.
Introduction
The assessment of metabolic stability, i.e., metabolic intrinsic clearance (CL int ), is presently a standard procedure in drug discovery programs. It is used both for ranking compounds with respect to metabolic stability and for predictions of metabolic clearance in animals and humans (Ito and Houston, 2005) . Because of the large number of new compounds emerging from lead generation and lead optimization programs, there is a need for a reliable and fast assay (Rodrigues, 1997) . A standard approach for the derivation of CL int is by fitting a mono exponential decay (EXP) model to a single depletion curve or by linear regression of the log concentration versus time. This approach is usually done with a starting concentration (C 0 ) of 1 M and under the assumption that the enzymatic reactions occur during linear conditions, i.e., the investigated concentration range is well below the overall K m of the reaction (Obach, 1999) . If this is not the case, it is probably more appropriate to adopt a Michaelis-Menten (MM) model described by V max and K m (Sjögren et al., 2009 ). The approach of most experimental design is arbitrary and constructed from empirical knowledge. The output is mostly validated by comparing scaled parameters to measured in vivo clearance. To increase the efficiency of various stages in drug development, optimal experimental design has been used (Pronzato and Walter, 1985; Mentre et al., 1997) . This method has been used mostly to optimize sample times, but it is also possible to optimize other design variables (Foracchia et al., 2004) . Furthermore, when optimizing more than one continuous design variable, the simultaneous optimization approach should be considered (Nyberg et al., 2009) . The aim of this study was to propose an optimal design, in respect of C 0 and sampling times, for estimation of CL int in a screening environment. single enzymatic route. A reference data set, including 2703 CL int measurements of individual compounds, was provided from AstraZeneca's database (AstraZeneca, Mölndal, Sweden) . No analyses of any kind were performed on the basis of the reference data set. The reference data set was only used for CL int distribution comparisons to the test data set and as an illustration of a parameter space obtained from an authentic metabolic screen. Pie charts of the distribution of metabolic stability of the experimental data set (at a protein concentration of 1 mg/ml) and reference data set (at a protein concentration of 0.5 mg/ml) are shown in Fig. 1 . Compounds are classified on the basis of in vitro half-life (t 1/2 ), according to the following empirical system previously used in AstraZeneca laboratories: stable (t 1/2 Ͼ115 min), measurable unstable (115 min Ͼ t 1/2 ; Ͼ2.8 min), and immeasurable unstable (t 1/2 Ͻ2.8 min).
Outline of the Workflow. The main objective of this study was to derive a general optimal experimental design for a screening environment, and this created some limits for the optimization variables. The design was restricted to a maximum of 15 samples, and the variables that could be modified to obtain the optimal experiment were C 0 (range, 0.01-100 M) and time point of sampling (range, 0 -40 min). A test data set was collected from the literature comprising V max /K m pairs, and these couples were treated as individual drug compounds. The first step was to derive an individual optimal experimental design for each compound. Simulations and estimations, i.e., generation of concentration time data (including noise) and fitting, of both the MM and EXP model for estimation of CL int , were then performed for each compound and with their respective optimal experimental design. Those compounds whose CL int could be estimated with an acceptable error [relative standard error (RSE) Ͻ50%], using either one of the used models, were included in the development of a general optimal experimental design. Compounds with an RSE Ͼ50% in CL int were excluded because these compounds could not constructively contribute to the optimization process of the general design. The general optimal design (G-OD) was consequently generated based on a subdataset containing the compounds remaining after the first step. This general design was then pragmatically adjusted in a third step to better suit experimental conditions. The fourth step was to carry out simulations and estimations for all compounds included in the original data set, i.e., including those excluded in the second step, with both the final optimal design (constructed through pragmatic modifications in step 3) and a conventional design. Finally, results [RSE and root mean square error (RMSE) of the estimates] were compared between the final optimal design and the conventional design.
Experimental Conditions. The following experimental conditions were used for the optimal design and simulations: 1) no loss of enzymatic activity during the incubation; 2) protein binding was assumed to be negligible; and 3) the assay was performed at a protein concentration of 1 mg/ml, selected due to the very low turnover of the majority of compounds in the test dataset at a protein concentration of 0.5 mg/ml. t 1/2 was calculated as t 1/2 ϭ ln(2)/(CL int ϫ protein concentration), where CL int and protein concentration are expressed as ml ⅐ min Ϫ1 ⅐ mg Ϫ1 protein and mg protein ml Ϫ1 , respectively. One of the most crucial factors enabling the estimation of rate constants is the signal-to-noise ratio, i.e., a sufficiently high turnover to detect depletion over time. Turnover is dependent on the ability of the enzyme to metabolize the substrate and the amount of protein present, i.e., protein concentration in the incubation. Because the selected protein concentrations may vary between assay setups at different laboratories, all results are related to turnover, i.e., t 1/2 , rather than CL int , to enable meaningful comparisons.
Standard Design. A commonly adopted design, with respect to C 0 and sampling, for estimation of CL int is incubation at a single C 0 , conducted in several replicates, including multiple samples taken throughout the incubation. The selected C 0 , total number of sample replicates, and length of the incubation time vary between research groups. However, in this study, we use a design conducted in triplicates, at C 0 ϭ 1 M with sampling at 0, 10, 20, 30, and 40 min as the standard design (STD-D). As a result, this design consisted of a total of 15 samples.
Simultaneous Optimization of the Experimental Design. A one-compartment pharmacokinetic model with an explicit solution to the nonlinear elimination was used, i.e., an integrated form of the MM equation (Beal, 1983) . The design for a new drug compound comprised 15 elementary designs (groups) with one sample and one dose (C 0 ) for each. It was important to restrict the number of samples to the same amount used for STD-D, because a small number of samples are a key feature of screening assays. The samples were limited between 0 and 40 min, and the C 0 was limited between 0.01 and 100 M. A lower limit of quantitation (LLOQ) for the concentrations was set to 0.01 M, and a residual variability consisting of a combined proportional (7.5%) and additive (S.D. ϭ 0.00185) error (together; 20% CV at a concentration of LLOQ) was assumed. The level of proportional error was chosen on the basis of the previous published results, and a 20% CV is commonly used for determining the LLOQ in bioanalytical method validations (Sjögren et al., 2009) . First, individual optimal designs (IOD) were performed for each V max /K m pair. Data sets representing the 76 compounds (i.e., the 76 combinations of V max and K m ) were then simulated with the MM model and the described error model by using the start concentrations and sampling times in respective IOD. CL int , V max , and K m were then estimated both by fitting the MM and the EXP model, respectively, to the generated data sets. All of the simulations and estimations were performed with NONMEM VII (Beal et al., 2009 ) by using the FOCEI method and were repeated 500 times for each compound to assess the optimal relative standard error (RSE) for each CL int . Those compounds that returned a CL int with RSE Ͼ50% after both IOD-MM and IOD-EXP analysis were excluded from the dataset when generating the G-OD. The rationale for this was to reduce the influence of compounds deemed uninformative under the imposed restrictions. The exclusion criteria led to the omission of 24 of 76 compounds. Moreover, for the design to be optimal for numerous drug compounds with different V max and K m values, a modified expectation of determinant (ED)-optimal design criterion with penalty was optimized in PopED version 2.10. In brief, the ED parameters' prior parameter distribution was a multivariate nonparametric distribution of the remaining 52 pairs of V max and K m values. The penalty function was formulated to find a G-OD that (on average) was closest to all the IOD (IOD-MM). Given this, the objective function value (OFV) to maximize ranged from 0 to 52. This could be interpreted as a sum of information relative to the IOD-MM (in percentage) of the included compounds. For example, an OFV of 52 corresponds to the best possible design, i.e., the G-OD is equally as good as the IOD-MM for every compound. Furthermore, an OFV of 0 corresponds to a FIG. 1. Pie charts of the distribution of metabolic stability, displayed as in vitro half-life (t 1/2 ), of the experimental data set (at a protein concentration of 1 mg ⅐ ml
Ϫ1
) and reference data set (at a protein concentration of 0.5 mg ⅐ m Ϫ1 l). Classification was as follows: stable, t 1/2 Ͼ115 min; measurable unstable, 2.8 min Ͻ t 1/2 Ͻ115 min; and immeasurable unstable, t 1/2 Ͻ 2.8 min.
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at ASPET Journals on July 7, 2017 dmd.aspetjournals.org Downloaded from general design with no information compared with the IOD-MM. After the G-OD with the highest OFV was found, the last step was to fashion one, for laboratory practice suitable pragmatic optimal design (OD). This was done by pragmatic modifications of the G-OD, based on the authors' empirical experience. Examples of modifications were rounding off C 0 and adjusting C 0 to better fit into dilution series. Again, 500 simulations and re-estimations were performed for all compounds with this design, i.e., OD, and the analysis was performed both with MM and EXP. The results from the pragmatic optimal design analyzed with MM (OD-MM) and EXP (OD-EXP) were then compared with the STD-D with respect to bias and precision (RMSE) in CL int , V max , and K m estimates. To ensure a fair comparison between the designs, the relative difference in RMSE used the minimal RMSE of the OD estimated with MM or EXP,min(OD-MM, OD-EXP) and compared this relative to the minimum RMSE of the STD-D estimated with either MM or EXP,min(STD-D-MM, STD-D-EXP). Designs were considered to perform equally well, for a specific compound, if the relative difference in RMSE between the models was less than 10%.
Results
The distributions of the IOD C 0 and time points for sample collection are shown in Fig. 2 . These designs were solely used for sorting out the compounds to be used in the generation of the G-OD. A clear trend for high and low C 0 was shown as well as a strong indication that sampling at t ϭ 40 min was most favorable regardless of C 0 . The explanation for this latter behavior is that the possibility to accurately determine the depletion rate is increased with increased difference between the concentration at the sampling point and C 0 , i.e., the signal-to-noise ratio is increased. The experimental designs obtained and used in the study (G-OD, OD, and STD-D) are displayed in Table 1 . Respective design performance, expressed as theoretical OFV, was 28, 17, and 0.011 for G-OD, OD, and STD-D, respectively. The drop in OFV for OD in relation to G-OD was considered minor in view of the OFV of STD-D, suggesting only a modest reduction in the efficiency of the design. Plots of OD and STD-D performance are displayed in Fig. 3 as RMSE (percentage) versus t 1/2 and RSE (percentage) versus t 1/2 . At low t 1/2 (t 1/2 Ͻ130 min), OD-MM generally performed better, i.e., lower RMSE, than OD-EXP and vice versa for t 1/2 Ͼ130 min (Fig. 4) . OD generated a better result (RSE) for 99% of the compounds and an equal or better result (RMSE) for 78% of the compounds. In addition, for a significant fraction of the compounds, it was possible with OD to determine V max and K m with an RMSE Ͻ30% (V max , 29% of the compounds; K m , 26% of the compounds) (indicated in Fig. 2) . This was only possible for 1% of the compounds using STD-D. In general, OD-MM performed better than STD-D for compounds t 1/2 Ͻ130 min and OD-EXP at t 1/2 Ͼ300 min. Comparisons of the different designs are summarized in Tables 2  and 3. FIG. 2. The distributions of C 0 and time point for sample collection (time) for generated IODs.
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Discussion
This study presents an experimental assay design optimized for metabolic stability screening in drug discovery, and it was developed with an optimal design tool for maximal likelihood estimation (PopED version 2.10). The results demonstrate that the output, as an estimation of CL int , was a general improvement on the standard approaches used today. Furthermore, high-quality estimates (RMSE Ͻ30%) of both V max and K m could be obtained for a considerable number (26%) of the investigated compounds.
The determination of metabolic stability, i.e., CL int , is presently a well established feature of drug discovery for the prediction of human hepatic clearance (Ito and Houston, 2005) . This is an important element in the selection process of optimal drug compounds. Because of the vast number of new compounds generated in lead generation and lead optimization programs, there is a need for a quick, reliable assay for an initial screen. Because compounds are excluded on the basis of this information, it is important that the information is as accurate as possible and not misleading. This study addresses two issues related to contemporary screening approaches. The first is the difficulty of determining slowly metabolized entities. The second is that the use of an exponential equation as an approximation of the MM equation, on the assumption that the reaction occurs under linear conditions, might result in inaccurate estimates of CL int . The hypothesis was that the negative influence of these two issues could be minimized by using optimal experimental design. Previous studies have reported different approaches to optimize the estimations of enzyme kinetic parameters for simple or complex enzyme systems (Endrenyi and Chan, 1981; Bardsley et al., 1996; Kakkar et al., 2000; Murphy et al., 2003; Yang et al., 2007; Youdim et al., 2010) . In addition, for basic information of the compounds' metabolic stability, the use of a single-time-point practice has been shown (Di et al., 2004) . To our knowledge, however, this is the first article that shows the advantage of optimal design theory to improve metabolic stability screening assays in the drug industry.
The overall trend of CL int for the compounds included in the test data set was lower than that of the reference data set. This was because single metabolic reactions for compounds metabolized by several metabolic pathways were considered as separate entities metabolized by that single pathway. One other contributing factor is that many of the metabolic reactions originated from marketed drugs, which are generally relatively metabolically stable. To be more representative of a real screening situation, i.e., to increase similarity to the reference data set, the turnover was increased by increasing the protein concen- tration for the simulations. However, because one of the goals was to increase the performance for slowly metabolized compounds, it was important to include a considerable number of these compounds. A protein concentration of 1 mg/ml was chosen as a midpoint between these two aspects. OD returned for 99% of the data set better RSE in CL int estimates than STD-D did, and the average improvement was 49%. This result was not surprising, because the optimal experimental design theory minimizes the expected parameter uncertainty (RSE) for an experiment. However, note that OD also returned CL int values with equally good or better RMSE in a majority (78%) of the cases. Because RMSE is the combined value of precision and accuracy, these results speak to the benefits of the OD approach. Analysis of high CL int entities required analysis with the MM, whereas compounds with low CL int required analysis with EXP. In a real situation, it is important to have methods to discriminate between the MM and EXP models and to choose the better of the two. This dilemma could be addressed by using both OD and MM for estimation and then choosing the better output with normal modeling discrimination methods, such as an analysis of the Akaike criteria, the log likelihood, conditional weighted residual, and so on. One alternative possibility, albeit less sophisticated, is to stipulate a crude rule, on the basis on the available information, for when to use either analysis method. Our results suggest that entities with a t 1/2 Ͻ130 min should be analyzed with the MM because this generated better results than EXP in this region. In addition, all estimates of CL int within this region were returned with an RMSE Ͻ30%. A half-life of 130 min, under linear conditions, corresponds to a turnover of 19% after 40 min; therefore, would a direct comparison of the concentration at 40 min toward C 0 for the lowest concentration used (0.45 M for OD) indicate whether it is preferable to use MM or EXP for analysis. If the turnover is less than 19% at 0.45 M, this study suggests that data analysis with EXP is preferred. It is interesting to note that STD-D generally performed better than OD for compounds with a t 1/2 between 130 and 300 min, whereas OD-EXP generally performed better than STD-D for entities with a t 1/2 Ͼ300 min. This behavior is hard to explain with the available data, and additional investigations will be necessary to better elucidate this behavior. Note that OD-EXP was able to return CL int with RMSE Ͻ100% for compounds with t 1/2 as high as 1800 min, i.e., a total turnover of 1.5%. An expected error of 100% is large, but if the magnitude of error is known, such information might still be useful for rough predictions of metabolic clearances. Nevertheless, because the majority (70%), of the compounds from an authentic metabolic screen (Fig. 1, reference data set) was associated with a t 1/2 Ͻ115 min, OD-MM is considered to be the preferred assay design and method of analysis.
For many compounds (26%), it was possible with OD-MM to discriminate and estimate both V max and K m with a low expected error (RMSE Ͻ30%). The results indicated that the determinative factor for this discrimination was primarily turnover, because discrimination was only possible for compounds with t 1/2 Ͻ40 min. The result did not indicate that the value of K m had any significance for the estimations. In theory, information of when saturation occurs, i.e., proportionality changes between concentration and reaction rate, needs to be available to make this distinction. However, because 50% of the compounds included in the reference data set had a t 1/2 Ͻ40 min, this result indicates that a lot of information can be gained in an authentic screening environment. Information about K m may be very useful, because it reflects the potential of saturation of the metabolic reaction. As a consequence, drugs with low K m values are at risk of showing nonlinear kinetics in an in vivo situation. For drugs with a narrow therapeutic concentration range, a supraproportional dose-exposure relationship might lead to severe consequences. However, nonlinear kinetics is not solely dependent on metabolic saturation, because other factors, such as active/carrier-mediated membrane transport into drugeliminating organs, binding to plasma components, and absorption rate, might also contribute to this situation. Furthermore, because drug metabolism often occurs via several metabolic pathways, the parameters obtained with this method are more accurately defined as total V max and apparent K m . Nevertheless, this information is still useful for the reasons stated above.
The approach of using high and low C 0 automatically encompasses issues such as solubility (limiting high C 0 ) and LLOQ of the bioanalysis. To address the issue of solubility, we set a limit for C 0 of 100 M. This is a relatively high concentration, and many compounds are likely to have a lower solubility at pH 7.4. Additional studies are needed to investigate the implications of this issue and to develop an approach to handle them. An additional requirement for the approach suggested in this study is the simultaneous model analysis of all data Turnover is expressed as in vitro half-life (t 1/2 ) in minutes. For both the STD-D and the OD, the results are based on the better estimate derived by using either the MM model or an EXP model. generated. This includes the use of sophisticated software capable of nonlinear regression and weighted residuals. The method is also constructed so that no measurements are performed at t ϭ 0, i.e., C 0 . C 0 measurements would automatically render twice as many samples as suggested. Because a low number of samples are crucial in a screen, this should be avoided. However, the practice of not measuring C 0 is already used in metabolic screening assays today. It is common for reactions in several wells in a multiple-well plate to be commenced simultaneously. The reactions are stopped at different time points by addition of organic solvent, and the concentration in each well is measured. It is assumed that every well had the same initial concentration because no individual C 0 measurement in individual wells is performed. The same assumption can be made when using different C 0 values, as suggested in this study, if the dilution and dispensing steps are well validated. We consider that the OD approach suggested in this article has the most relevance in improving lead optimization screens. The STD-D was, in most cases, shown to work sufficiently well for crude classifications of compounds metabolic stability. However, accurate and precise estimates are of greater importance when ranking and evaluating chemical analogs as a step in the selection process of the most potential new drug candidate. Information of compounds K m would also be of interest during this process because this aspect could be included in the selection process. The results indicated that application of the OD would facilitate estimation of K m for compounds with a t 1/2 Ͻ40 min. One could speculate that this quality could significantly add to the information output of an authentic screen of lead compounds, because approximately 50% of the compounds included in the reference data set showed this behavior. It is unfortunate that this could not be analyzed in detail because no information of V max and K m were available for these compounds. However, one possible approach to further investigate this aspect could be to assign the K m values included in the test data set to the compounds in the reference data set.
In summary, this study shows that the widespread approach applied to study depletion from a single starting concentration with multiple sampling points distributed over the incubation time is suboptimal. Our results show that running depletion curves with more than one start C 0 generates equal or better estimates of CL int without increasing the total number of samples. In addition, data analysis performed with the MM enables the primary enzyme kinetic parameters, V max and K m , to be estimated in many cases. Hence, the OD suggested in this study (Table 1 ) is believed to be at least as good as or better than the standard approach (STD-D). Still, additional optimization is almost certainly needed for specific laboratories and applications.
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Supplement Table I:
The test data set used in the optimization of the experimental design. The data set is a rework from data collected in the work of Proctor et al., 2004 
